

Agilent, Akoya Biosciences to develop multiplex IHC solutions

Jan. 17, 2023—[Agilent Technologies](#) announced a partnership with [Akoya Biosciences](#) to develop chromogenic and immunofluorescent multiplex assays that include spatial analysis for biopharma companies developing precision cancer therapeutics. The agreement aims to deliver an end-to-end multiplex solution integrating Agilent's Dako Omnis staining instrument and Akoya's Phenolmager HT imaging platform.

"We are delighted to be partnering with Akoya to create industry-leading products and services for multiplex chromogenic and immunofluorescence tissue assays," Sam Raha, president of Agilent's diagnostic and genomics group, said in a press release. "This partnership enables an ecosystem that assists the development of novel precision cancer therapeutics and offers a streamlined workflow to our joint customers in the clinical research market to meet the needs of future clinical diagnostics."

Under a separate value-added reseller agreement, Akoya will distribute and resell Dako Omnis as a part of the end-to-end multiplex solution.